--- title: "Telix Pharmaceuticals (TLX) news: offering and convertible notes" url: "https://aibio.space/companies/telix-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "TLX offering and convertible notes news: Telix Pharmaceuticals prices upsized US$600 million convertible bonds due 2031." --- TLX Telix Pharmaceuticals Limited ASX · Australia # Telix Pharmaceuticals (TLX) news TLX offering and convertible notes news Financings · 2026-04-14 ## [Telix Pharmaceuticals prices upsized US$600 million convertible bonds due 2031](https://aibio.space/news/telix-pharmaceuticals-prices-upsized-us-600-million-convertible-bonds/) Telix raised its convertible notes offering from US$550 million to US$600 million and will use most of the money to buy back its 2029 convertible bonds. The reference price for the conversion terms was set at an 8.0 per cent discount to the closing share price. ## Latest Telix Pharmaceuticals news We have not published a story on Telix Pharmaceuticals yet. When there is news, it will appear here. ## Telix Pharmaceuticals at a glance - **Ticker**: TLX - **Listing**: ASX - **Country**: Australia - **Cash, Dec 31, 2025**: $141.9 million ### Related companies - [Ceryvyn Therapeutics](https://aibio.space/companies/ceryvyn-therapeutics/) ASX: CYV - [Immutep](https://aibio.space/companies/immutep/) ASX: IMM - [Polynovo](https://aibio.space/companies/polynovo/) ASX: PNV - [CSL](https://aibio.space/companies/csl/) ASX: CSL - [Amplia Therapeutics](https://aibio.space/companies/amplia-therapeutics/) ASX: ATX - [Incannex Healthcare](https://aibio.space/companies/incannex-healthcare/) NASDAQ: IXHL - [Cambium Bio](https://aibio.space/companies/cambium-bio/) ASX: CMB - [Kazia Therapeutics](https://aibio.space/companies/kazia-therapeutics/) NASDAQ: KZIA ### Also on ASX - [LTR Pharma](https://aibio.space/companies/ltr-pharma/) LTP - [Immuron](https://aibio.space/companies/immuron/) IMC - [Prescient Therapeutics](https://aibio.space/companies/prescient-therapeutics/) PTX - [Firebrick Pharma](https://aibio.space/companies/firebrick-pharma/) FRE - [Tissue Repair](https://aibio.space/companies/tissue-repair/) TRP - [Nexalis Therapeutics](https://aibio.space/companies/nexalis-therapeutics/) NX1 ## Telix Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$803.8 million](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/) | [$516.6 million](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/) | | Research and development | [$171.2 million](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/) | [$127.9 million](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/) | | Net income (loss) | [-$7.1 million](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/) | [$33.7 million](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/) | | Cash from operations | [-$17.3 million](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/) | [$27.5 million](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/) | | Cash and equivalents | [$141.9 million](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/) | [$440.0 million](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $141.9 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Telix Pharmaceuticals Has Telix Pharmaceuticals raised money recently? Our latest story on this, dated Apr 14, 2026: "Telix Pharmaceuticals prices upsized US$600 million convertible bonds due 2031". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/telix-pharmaceuticals-prices-upsized-us-600-million-convertible-bonds/). Has Telix Pharmaceuticals sold convertible notes? Our latest story on this, dated Apr 14, 2026: "Telix Pharmaceuticals prices upsized US$600 million convertible bonds due 2031". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/telix-pharmaceuticals-prices-upsized-us-600-million-convertible-bonds/). What is the ticker symbol of Telix Pharmaceuticals? Telix Pharmaceuticals Limited trades under the ticker TLX on ASX. Where is Telix Pharmaceuticals listed? Telix Pharmaceuticals Limited is listed on ASX. Our directory also records these other listings: GETTEX:T3X; LS:A2H7JK; LSX:A2H7JK; NASDAQ:TLX; OTC:TLPPF. What is the SEC CIK of Telix Pharmaceuticals? The SEC Central Index Key (CIK) for Telix Pharmaceuticals Limited is 2007191. Its filings are on SEC EDGAR. How many shares does Telix Pharmaceuticals have outstanding? 338,777,049 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-02-20. Which country or territory is Telix Pharmaceuticals listed under? Our directory records Telix Pharmaceuticals Limited under Australia. What does Telix Pharmaceuticals do? Our directory classifies Telix Pharmaceuticals Limited as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Telix Pharmaceuticals? The ISIN recorded for Telix Pharmaceuticals Limited is AU000000TLX2. Does aibio.space cover Telix Pharmaceuticals? aibio.space lists Telix Pharmaceuticals Limited among 2,820 public biotech companies and publishes its news here as stories appear. Where is Telix Pharmaceuticals incorporated? SEC records list its state or country of incorporation as C3. What was Telix Pharmaceuticals's revenue last year? $803.8 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Telix Pharmaceuticals profitable? Telix Pharmaceuticals Limited reported a net loss of $7.1 million for the fiscal year ended Dec 31, 2025, and used $17.3 million of cash in operations, per its annual report to the SEC. How much does Telix Pharmaceuticals spend on research and development? $171.2 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Telix Pharmaceuticals have? $141.9 million in cash at Dec 31, 2025, per its 20-F. ## Investor discussion: Telix Pharmaceuticals Members talk about Telix Pharmaceuticals (TLX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Telix Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-04-14 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/2007191/000114036126014495/ef20070387_ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open ASX:TLX on TradingView](https://www.tradingview.com/symbols/ASX-TLX/). ## SEC filings and registration - **SEC name**: Telix Pharmaceuticals Ltd - **CIK**: 2007191 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: TLX (Nasdaq), TLPPF (OTC) - **State or country of incorporation**: C3 - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 55 FLEMINGTON ROAD, NORTH MELBOURNE, Australia, 3051 - **Phone**: 61 3 9093 3855 - **Shares outstanding**: 338,777,049 as of 2025-12-31 (20-F filed 2026-02-20) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/2007191/000162828026066581/q32026resultsannouncement.htm) filed 2026-10-21 - [6-K](https://www.sec.gov/Archives/edgar/data/2007191/000162828026063875/telix-6kbipassgainsfdafast.htm) filed 2026-09-30 - [6-K](https://www.sec.gov/Archives/edgar/data/2007191/000162828026062813/telix-6ktelixanditmjoinfor.htm) filed 2026-09-21 - [6-K](https://www.sec.gov/Archives/edgar/data/2007191/000162828026061892/telix-6kpixclarafdaapproval.htm) filed 2026-09-14 - [6-K](https://www.sec.gov/Archives/edgar/data/2007191/000162828026059952/telix-6kphase3bipassenroll.htm) filed 2026-09-02 - [6-K](https://www.sec.gov/Archives/edgar/data/2007191/000162828026059684/telix-6kappointmentofdavid.htm) filed 2026-09-01 - [6-K](https://www.sec.gov/Archives/edgar/data/2007191/000162828026058126/tlx-20260630.htm) filed 2026-08-20 - [6-K](https://www.sec.gov/Archives/edgar/data/2007191/000162828026048922/telix-6kforq22026tradingup.htm) filed 2026-07-21 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002007191), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Telix Pharmaceuticals Limited is a public biotech or pharmaceutical company listed on ASX under the ticker TLX, recorded under Australia. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Telix Pharmaceuticals Limited - **Ticker**: TLX - **Listing**: ASX - **Country or territory**: Australia - **Business scope**: Biotechnology - **ISIN**: AU000000TLX2 - **Other listed symbols**: GETTEX:T3X; LS:A2H7JK; LSX:A2H7JK; NASDAQ:TLX; OTC:TLPPF - **Last quote in directory**: 2026-10-22 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/ASX-TLX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/telix-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Telix Pharmaceuticals (TLX) news: offering and convertible notes", 2026-10-31, https://aibio.space/companies/telix-pharmaceuticals/